AALL1631: International Phase 3 trial in Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL) testing Imatinib in combination with two different cytotoxic chemotherapy backbones

Contact:

NCT Number:

Protocol:

AAAS2621

Study Status:

Active/Enrolling

Population:

Pediatrics/Adult

Phase:

III

This phase 3 study is examining the best treatments for Philadelphia chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL). The goal of this study is to see if using a less toxic chemotherapy regimen in combination with Imatinib can effectively treat standard risk Ph+ ALL. Patients with high risk Ph+ ALL will receive more intensive chemotherapy followed by stem cell transplant.

Are you Eligible? (Inclusion Criteria)

  • must be at least greater than 1 year and less than 21 years of age
  • Patients must be newly diagnosed
  • Patients must also meet all eligibility criteria as outlined in the study protocol

Specialty Area(s)

Leukemia, Childhood and Adolescent Cancers (Pediatric), Precision Oncology

Principal Investigator

Trial Location(s)

CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032